Bayer invests USD 50 Million in eGenesis Series B financing round

Originally posted on Bayer.com

Investment to support development of human-compatible xeno organs to address the global organ shortage crisis / eGenesis with lead program in kidney transplantation

Bayer Photo
Research in the eGenesis laboratory, Cambridge, MA, USA

Leverkusen, Germany and Boston, Mass., November 7, 2019 – eGenesis, a biotechnology company utilizing breakthrough gene editing technologies for the development of effective human-compatible organs to address the global organ shortage, successfully completed a USD 100 million Series B financing. The financing was led by Fresenius Medical Care Ventures (FMCV), with participation from new investors including Leaps by Bayer and Wellington Partners. Existing investors, including, but not limited to, ARCH Venture Partners, Biomatics Capital, Alta Partners, and Khosla Ventures, all participated.

eGenesis is committed to helping solve the global organ shortage by pioneering an alternative source of human-compatible organs. It is currently estimated that there are between 1.5 to 2 million people on the organ transplant waitlist globally. This financing will enable the acceleration of the eGenesis kidney xenotransplant program into the clinic, as well as support advancement of a range of other xenotransplant programs across islet cell, liver, heart, and lung. The focus of the company is to rapidly advance an entirely new set of options across the transplantation field.

“Leaps by Bayer” is built for the specific purpose of tackling fundamental breakthrough solutions in the fields of health and nutrition with the help of new technologies. Sustainable organ replacement is one of the ten areas of engagement and investment (called “leaps”) for Leaps by Bayer. “We believe eGenesis is poised to revolutionize the entire organ transplantation market. This could save lives in a way that was previously not thought possible just a few years ago,” noted Jürgen Eckhardt, Head of Leaps by Bayer. Eckhardt and Dr. Lucio Iannone will represent Leaps by Bayer by actively participating on the eGenesis Board of Directors.

“eGenesis has a bold vision to solve the organ shortage crisis through xenotransplantation,” said Paul Sekhri, president and chief executive officer of eGenesis. “As we look ahead, we are proud to partner with Leaps by Bayer who has demonstrated a commitment for ushering in paradigm-shifting advances in the life sciences that will bring forward tomorrow’s medicines.”

Kemal Malik, Member of the Board of Management, Bayer AG, and responsible for Innovation, added, “Within Bayer’s innovation strategy, Leaps is driving breakthrough invention at Bayer and the eGenesis approach represents a truly transformational option, addressing the unmet medical need of patients suffering from a disease where organ transplantation could be a potentially lifesaving treatment.”

Leaps by Bayer, a unit of Bayer is investing into solutions to some of today’s biggest challenges in health and agriculture. Previous Leaps investments into potentially breakthrough technologies include Casebia Therapeutics (Cure genetic diseases), BlueRock Therapeutics (Regenerate lost tissue function), Joyn Bio (Reduce environmental impact of farming) as well as Khloris, Century Therapeutics and Pyxis Oncology (Prevent and cure cancer).

Leave a Comment

Your email address will not be published. Required fields are marked *

*

Latest News

money, native, villanueva, Decolonizing Wealth

‘Decolonizing Wealth:’ Edgar Villanueva Discusses How Money Can Heal Native American Communities

Edgar Villanueva is an expert on philanthropy and a member of the Lumbee Native American Tribe in North Carolina. After spending years in the institutional philanthropic sector, he wrote “Decolonizing Wealth: Indigenous Wisdom to Heal Divides and Restore Balance,” which looks into how money — which has often been used…

Miller

Stephen Miller, the Man Behind Trump’s Immigration Agenda, Promoted White Nationalism and Racism: Report

A report by the Southern Poverty Law Center (SPLC) analyzed more than 900 emails leaked from Stephen Miller that he sent to the far-right website Breitbart. The emails reveal that Miller, a White House senior adviser for President Donald Trump, used white supremacist propaganda and literature to shape Breitbart’s articles….

webcam

Trump Administration Plans to Livestream Building of Border Wall

Senior officials in the Trump administration want to put in webcams to livestream building parts of the border wall. The Washington Post reported that Jared Kushner and other senior White House officials are going against objections from the U.S. Army Corps of Engineers and senior U.S. Customs and Border Protection…